Literature DB >> 8855814

p53 mutations in adrenal tumors: Caucasian patients do not show the exon 4 "hot spot" found in Taiwan.

M Reincke1, C Wachenfeld, P Mora, A Thumser, C Jaursch-Hancke, S Abdelhamid, G P Chrousos, B Allolio.   

Abstract

Mutations in the p53 tumor suppressor gene are frequently present in human cancers but have rarely been described in benign tumors. We previously reported mutations in the "hot spots" between exons 5-8 of the p53 gene in adrenocortical carcinomas but not in adenomas. Recently, a previously unknown hot spot in exon 4 of the p53 gene was described in adrenal adenomas and pheochromocytomas of Taiwanese patients. We, therefore, investigated whether these mutations are also present in Caucasian patients from the U.S. and Europe. We analyzed tumor tissue of 12 aldosterone-producing adenomas, 7 cortisol-producing adenomas, and 6 pheochromocytomas. Overexpression of the p53 protein was investigated by immunohistochemistry. Point mutations within exon 4 were identified by polymerase chain reaction (PCR) amplification and direct sequencing of the PCR product. The pYNZ22 microsatellite located on chromosome 17p, close to the p53 gene, was used to screen for allelic loss (LOH) of the p53 gene. Overexpression of p53 was not identified in any of the adenomas and pheochromocytomas. Point mutations within exon 4 were found in 0/25 tumors. LOH was present in 1/13 informative adenomas and 0/2 informative pheochromocytomas. We conclude that p53 mutations do not play a major role in the tumorigenesis of adrenal adenomas and pheochromocytomas of Caucasian patients. Thus, ethnic and environmental factors may be responsible for the mutational spectrum found in Taiwanese patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8855814     DOI: 10.1210/jcem.81.10.8855814

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.

Authors:  Junna Ye; Yan Qi; Weiqing Wang; Fukang Sun; Qin Wei; Tingwei Su; Weiwei Zhou; Yiran Jiang; Wenqi Yuan; Jianfei Cai; Bin Cui; Guang Ning
Journal:  Endocrine       Date:  2012-02-04       Impact factor: 3.633

2.  The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas.

Authors:  K Y Lam; C Y Lo; N M Wat; J M Luk; K S Lam
Journal:  J Clin Pathol       Date:  2001-06       Impact factor: 3.411

3.  p53 protein and its messenger ribonucleic acid in human adrenal tumors.

Authors:  V Adleff; K Rácz; M Tóth; I Varga; A Bezzegh; E Gláz
Journal:  J Endocrinol Invest       Date:  1998-12       Impact factor: 4.256

Review 4.  Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.

Authors:  Hilde Dannenberg; Paul Komminoth; Winand N M Dinjens; Ernst Jan M Speel; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

5.  Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis.

Authors:  Thomas J Giordano; Dafydd G Thomas; Rork Kuick; Michelle Lizyness; David E Misek; Angela L Smith; Donita Sanders; Rima T Aljundi; Paul G Gauger; Norman W Thompson; Jeremy M G Taylor; Samir M Hanash
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

Review 6.  Molecular pathology of adrenal cortical tumors: separating adenomas from carcinomas.

Authors:  Thomas J Giordano
Journal:  Endocr Pathol       Date:  2006       Impact factor: 4.056

7.  Apoptosis control and proliferation marker in human normal and neoplastic adrenocortical tissues.

Authors:  G P Bernini; A Moretti; P Viacava; A G Bonadio; P Iacconi; P Miccoli; A Salvetti
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.